Use of pteridinone derivative serving as EGFR inhibitor
AssigneeEast China University of Science and Technology
InventorsHonglin Li, Yufang Xu, Zhenjiang Zhao, Wei Zhou, Yuqiong Xu, Deheng Sun, Xia Wang, Zhuo Chen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.
Claims11
A compound of formula I or a pharmaceutical acceptable salt thereof:
- wherein,
- R1 is independently selected from the group consisting of substituted or unsubstituted phenyl, and optionally substituted C3-C8 cycloalkyl;
- A is a divalent radical -A′-;
- A′ is a benzene ring, or a five- or six-membered nitrogen-containing heterocycle;
- R2 is independently selected from the group consisting of C2-C4 alkenyl substituted acylamino and substituted or unsubstituted C2-C4 alkenyl substituted acyl;
- m is 0;
- R7 is independently selected from the group consisting of:
- and
- R3, R4, R5 and R6 are independently selected from the group consisting of H, substituted or unsubstituted C1-C6 alkoxy, and substituted or unsubstituted C1-C6 alkyl;
- provided that when R1 is H and m is 0, R3, R4, R5 and R6 are not each H;
- and
- when R1 is H, m is 0, A′ is a benzene ring and R7 is
- if one of R3 and R6 is a methoxy, the other is not H.
A compound or a pharmaceutical acceptable salt thereof selected from the group consisting of:
A compound or a pharmaceutical acceptable salt thereof selected from the group consisting of:
Dependencies are inferred from the claim text.